International differences in cancer survival rates: The role of new drug launches

International Journal of Healthcare Technology and Management

Volumn 10, Issue 3, 2009, Pages 138-155

  Lichtenberg, Frank R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer; Drug launch; Innovation; Longevity; Neoplasm; Pharmaceutical; Survival

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CLADRIBINE; CLODRONIC ACID; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FLUDARABINE; INTERFERON; IRINOTECAN; LETROZOLE; METHOTREXATE; MITOXANTRONE; NAVELBINE; NEW DRUG; NILUTAMIDE; PACLITAXEL; PAMIDRONIC ACID; RALTITREXED; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; STREPTOZOCIN; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; DRUG MANUFACTURE; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEALTH CARE QUALITY; MATHEMATICAL ANALYSIS; PUBLIC HEALTH; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME;

EID: 66749171718     PISSN: 13682156     EISSN: None     Source Type: Journal    
DOI: 10.1504/IJHTM.2009.025818     Document Type: Article

References (15)

1. Bils, M. (2004) Measuring the Growth from Better and Better Goods, NBER Working Paper No. 10606, July, http://www.nber.org/papers/w10606, accessed 13 December 2006.
2. Bresnahan, T.F. and Gordon, R.J. (1996) The Economics of New Goods University of Chicago Press, Chicago.
3. Cancer Care Ontario (2006) Drug Formulary, http://www.cancercare.on.ca/index_plugformulary.htm, accessed 13 December.
4. Danzon, P., Wang, Y.R. and Wang, L. (2005) 'The impact of price regulation on the launch delay of new drugs - evidence from 25 major markets in the 1990s', Health Economics, Vol. 14, pp.269-292.
5. Ferlay, J., Bray, F., Pisani, P. and Parkin, D.M. (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5. version 2.0, IARC Press, Lyon, http://www-dep.iarc.fr/ GLOBOCAN/database.htm, accessed 13 December 2006.
6. Grossman, G.M. and Helpman, E. (1991) Innovation and Growth in the Global Economy, MIT Press, Cambridge.
7. Kyle, M.K. (2007) 'Pharmaceutical price controls and entry strategies', The Review of Economics and Statistics, Vol. 89, No. 1, pp.88-99.
8. Lichtenberg, F. (2007) 'Pharmaceutical innovation and U.S. cancer survival, 1992-2003: Evidence from linked SEER-MEDSTAT data', Forum for Health Economics and Policy, Vol. 10, No. 1 (Frontiers in Health Policy Research), Article 1, http://www.bepress.com/fhep/10/1/1
9. Lichtenberg, F. (2005a) 'The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001', International Journal of Health Care Finance and Economics, Vol. 5, pp.47-73.
10. Lichtenberg, F. (2005b) 'Pharmaceutical knowledge-capital accumulation and longevity', in Corrado, C., Haltiwanger, J. and Sichel, D. (Eds.): Measuring Capital in the New Economy, University of Chicago Press, Chicago, pp.237-269.
11. Lichtenberg, F. (2005c) 'Availability of new drugs and Americans' ability to work', Journal of Occupational and Environmental Medicine Vol. 47, No. 4, April, pp.373-380.
12. Nordhaus, W. (2003) 'The health of nations: The contribution of improved health to living standards', in Murphy, K.M. and Topel, R.H. (Eds.): Measuring the Gains from Medical Research: An Economic Approach, University of Chicago Press, Chicago.
13. Pisani, P., Bray, F. and Parkin, D.M. (2002) 'Estimates of the worldwide prevalence of cancer for twenty-five sites in the adult population', Int. J. Cancer, Vol. 97, pp.72-81.
14. Romer, P. (1990) 'Endogenous technical change', Journal of Political Economy, Vol. 98, pp.S71-S102.
15. World Health Organization (2002) Revised Global Burden of Disease (GBD) Estimates, http://www.who.int/healthinfo/bodgbd2002revised/en/ index.html, accessed 13 December 2006.